Table of Content

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Distribution Channels
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Oncology Biosimilars Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Drug Class (Monoclonal Antibodies, G-CSF, Hematopoietic Agents, Others)
5.2.2. By Type of Cancer (Breast Cancer, Lung Cancer, Stomach Cancer, Prostate Cancer, Cervical Cancer, Blood Cancer, Brain Cancer, Others)
5.2.3. By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies)
5.2.4. By Region
5.2.5. By Company (2022)
5.3. Market Map
6. North America Oncology Biosimilars Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Drug Class
6.2.2. By Type of Cancer
6.2.3. By Distribution Channel
6.2.4. By Country
6.3. North America: Country Analysis
6.3.1. United States Oncology Biosimilars Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Drug Class
6.3.1.2.2. By Type of Cancer
6.3.1.2.3. By Distribution Channel
6.3.2. Canada Oncology Biosimilars Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Drug Class
6.3.2.2.2. By Type of Cancer
6.3.2.2.3. By Distribution Channel
6.3.3. Mexico Oncology Biosimilars Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Drug Class
6.3.3.2.2. By Type of Cancer
6.3.3.2.3. By Distribution Channel
7. Europe Oncology Biosimilars Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Drug Class
7.2.2. By Type of Cancer
7.2.3. By Distribution Channel
7.3. Europe: Country Analysis
7.3.1. Germany Oncology Biosimilars Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Drug Class
7.3.1.2.2. By Type of Cancer
7.3.1.2.3. By Distribution Channel
7.3.2. United Kingdom Oncology Biosimilars Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Drug Class
7.3.2.2.2. By Type of Cancer
7.3.2.2.3. By Distribution Channel
7.3.3. Italy Oncology Biosimilars Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecasty
7.3.3.2.1. By Drug Class
7.3.3.2.2. By Type of Cancer
7.3.3.2.3. By Distribution Channel
7.3.4. France Oncology Biosimilars Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Drug Class
7.3.4.2.2. By Type of Cancer
7.3.4.2.3. By Distribution Channel
7.3.5. Spain Oncology Biosimilars Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Drug Class
7.3.5.2.2. By Type of Cancer
7.3.5.2.3. By Distribution Channel
8. Asia-Pacific Oncology Biosimilars Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Drug Class
8.2.2. By Type of Cancer
8.2.3. By Distribution Channel
8.3. Asia-Pacific: Country Analysis
8.3.1. China Oncology Biosimilars Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Drug Class
8.3.1.2.2. By Type of Cancer
8.3.1.2.3. By Distribution Channel
8.3.2. India Oncology Biosimilars Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Drug Class
8.3.2.2.2. By Type of Cancer
8.3.2.2.3. By Distribution Channel
8.3.3. Japan Oncology Biosimilars Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Drug Class
8.3.3.2.2. By Type of Cancer
8.3.3.2.3. By Distribution Channel
8.3.4. South Korea Oncology Biosimilars Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Drug Class
8.3.4.2.2. By Type of Cancer
8.3.4.2.3. By Distribution Channel
8.3.5. Australia Oncology Biosimilars Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Drug Class
8.3.5.2.2. By Type of Cancer
8.3.5.2.3. By Distribution Channel
9. South America Oncology Biosimilars Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Drug Class
9.2.2. By Type of Cancer
9.2.3. By Distribution Channel
9.3. South America: Country Analysis
9.3.1. Brazil Oncology Biosimilars Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Drug Class
9.3.1.2.2. By Type of Cancer
9.3.1.2.3. By Distribution Channel
9.3.2. Argentina Oncology Biosimilars Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Drug Class
9.3.2.2.2. By Type of Cancer
9.3.2.2.3. By Distribution Channel
9.3.3. Colombia Oncology Biosimilars Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Drug Class
9.3.3.2.2. By Type of Cancer
9.3.3.2.3. By Distribution Channel
10. Middle East and Africa Oncology Biosimilars Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Drug Class
10.2.2. By Type of Cancer
10.2.3. By Distribution Channel
10.3. MEA: Country Analysis
10.3.1. South Africa Oncology Biosimilars Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Drug Class
10.3.1.2.2. By Type of Cancer
10.3.1.2.3. By Distribution Channel
10.3.2. Saudi Arabia Oncology Biosimilars Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Drug Class
10.3.2.2.2. By Type of Cancer
10.3.2.2.3. By Distribution Channel
10.3.3. UAE Oncology Biosimilars Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Drug Class
10.3.3.2.2. By Type of Cancer
10.3.3.2.3. By Distribution Channel
11. Market Dynamics
11.1. Drivers & Challenges
12. Market Trends & Developments
12.1. Recent Developments
12.2. Product Launches
12.3. Mergers & Acquisitions
13. Global Oncology Biosimilars Market: SWOT Analysis
14. Competitive Landscape
14.1. Teva Pharmaceuticals
14.2. STADA Arzneimittel AG
14.3. Shanghai Henlius Biotech Inc
14.4. Sandoz (Novartis) AG
14.5. Samsung Bioepis Co Ltd.
14.6. Pfizer Inc
14.7. Pfenex Inc.
14.8. Mylan Inc
14.9. Innovent Biologics Inc
14.10. Celltrion Healthcare Co Ltd
15. Strategic Recommendations
16. About Us & Disclaimer